SCIENCE
Problem: Significant access issues and unmet needs for patients with cognitive impairment
-
Care Pathways: Patients face fragmented care and long wait times in neurology and geriatrics, often exceeding 6 months.
-
Screening + Prevention: Only 15% of patients undergo PCP screening for treatable conditions; 35% of dementia cases could be prevented with risk factor modification. 1 in 3 people die with Alzheimer’s or another form of dementia
-
Diagnostic Challenges: Current Alzheimer's disease diagnostics are costly, invasive, and impractical for large-scale screening (e.g., PET, MRI, CSF studies).
-
Treatment Access: There is a considerable need for accessible FDA-approved monoclonal antibody treatments for eligible patients as efficacy is best earliest in the disease (similar to cancer)
-
Affordable Biomarkers: There is a scarcity of cost-effective biomarkers for evaluating MAB treatment risks, monitoring progress, and measuring amyloid clearance.
Solution: NeuroVision addresses gaps and delivers diagnostic and disease management solutions at scale
TECH-ENABLED SERVICES
AND TELEHEALTH PLATFORM
-
BrainHealth.net: Bridges gaps in care by starting the workup earlier and improving access to neurological care and treatment
-
Provider Partnerships: Facilitates pre-screening, pre-authorization, and CPT billing
-
Affordable Testing: Offers accessible genotyping, biomarker testing, and cognitive assessments
-
Lifestyle Programs: Provides science-based lifestyle intervention strategies
-
Retinal biomarkers: Identifies amyloid in the retina, a key indicator of Alzheimer’s and Cerebral Amyloid Angiopathy (CAA)
-
Regulatory Approval: FDA 510k cleared,
ISO 13485 certified
PROPRIETARY RETINAL IMAGING PLATFORM
Afina® Retinal Imaging System
High resolution autofluorescence retinal camera and cloud-based Afina® software medical device measures for early detection
Afina® Retinal Imaging System
High resolution autofluorescence retinal camera and cloud-based Afina® software medical device measures for early detection
-
Delivers predictions of cerebral amyloid status as a screen prior to PET / CSF, and Alzheimer’s treatment monitoring
-
Assessment of perivascular amyloid and other vascular changes for risk assessment (CAA and ARIA prediction)